Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides
Public ClinicalTrials.gov record NCT04676087. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Mogamulizumab and Extracorporeal Photopheresis (ECP) for the Treatment of Sézary Syndrome and Erythrodermic Mycosis Fungoides, a Phase 1b/2 Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase Ib/II trial investigates the side effects of mogamulizumab and extracorporeal photopheresis and to see how well they work in treating patients with Sezary syndrome or mycosis fungoides. Mogamulizumab (a humanized antibody) binds to CCR4, a protein often found in high amounts on T-cell lymphoma cells. Binding to these cells may slow their growth, as well as mark them for attack by the immune system. Extracorporeal photopheresis (ECP) is a standard treatment for cancers that affects the skin, and may work by killing some lymphoma cells directly and by boosting the body's immune response against other lymphoma cells. Giving mogamulizumab together with ECP may work better in treating patients with Sezary syndrome or mycosis fungoides compared to either therapy alone.
Study identification
- NCT ID
- NCT04676087
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 5 participants
Conditions and interventions
Interventions
- Extracorporeal Photopheresis Procedure
- Mogamulizumab Biological
- Quality-of-Life Assessment Other
Procedure · Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 20, 2021
- Primary completion
- Oct 10, 2023
- Completion
- Oct 10, 2023
- Last update posted
- Aug 12, 2024
2021 – 2023
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Emory University Hospital | Atlanta | Georgia | 30322 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Mycosis Fungoides trials
Other public records listing Mycosis Fungoides. Sorted by last update posted; newest first. Not a recommendation.
- NCT07714187: A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides Not yet recruiting
- NCT06580002: Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial Recruiting
- NCT05978141: A Registry for People With T-cell Lymphoma Recruiting
- NCT05944562: Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome Active, not recruiting
- NCT05838599: Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides Recruiting
- NCT05680558: Photopheresis in Early-stage Mycosis Fungoides Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04676087, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 12, 2024 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04676087 live on ClinicalTrials.gov.